NCNA News

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025

(NASDAQ:NCNA) EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held October 17-21, 2025 in Berlin, Germany (the “ESMO Congress 2025”).

September 3, 2025Clinical Trials

NuCana Q1 EPADS $(0.75)

NCNA

June 2, 2025

NuCana Prices Registered Direct Offering For Gross Proceeds Of ~$7M

NCNA

May 6, 2025

NuCana Q4 EPS £(0.01) Up From £(0.14) YoY.

NCNA

March 20, 2025

NuCana Q1 2024 GAAP EPS £(0.13) Up From £(0.15) YoY

NCNA

May 16, 2024

NuCana Presents Data On NUC-7738 At The European Society Of Medical Oncology Annual Meeting 2022

NCNA

September 12, 2022

NuCana Presents Data On NUC-3373 At The European Society Of Medical Oncology Annual Meeting 2022

NCNA

September 12, 2022